Drug intelligence / Profile preview

JZ-603

Development stage: Preclinical
Lead developer: Protheragen
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

JZ-603 is a preclinical-stage protein therapeutic candidate being developed by Protheragen for the treatment of allergic asthma and allergic rhinitis. The drug is designed to target and neutralize Immunoglobulin E (IgE), a central mediator in the type I hypersensitivity reactions that characterize allergic diseases. By sequestering IgE, JZ-603 prevents its binding to the high-affinity FcεRI receptors on mast cells and basophils, thereby inhibiting the release of histamine and other pro-inflammatory mediators responsible for airway inflammation and nasal symptoms.

Targets

FCGR2B (Fc gamma receptor IIB)

Beyond the preview

Go deeper on JZ-603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JZ-603.

Explore the full profile